Beverly Lybrand

Biography

Bev is an experienced healthcare executive with worldwide commercial business expertise in both pharmaceuticals and vaccines. She has spent the majority of career at Merck & Co. Inc., where she was instrumental in the successful commercialisation of more than 30 global brands, including major Merck products such as Singulair® in respiratory diseases; Gardasil®, a vaccine against cervical cancer & HPV diseases; and Mevacor®, Zocor® and Cozaar®/Hyzaar® in cardiovascular indications. Most recently, Bev served as SVP & General Manager at Merck's Neurosciences and Ophthalmology groups, during which time she was responsible for leading the commercialisation of Saphris®/Sycrest®, Bridion® and Maxalt® and for defining the commercial development strategies for multiple key programmes targeting migraine (telcagepant), schizophrenia, sleep disorders, Alzheimer's disease and Parkinson's disease. Prior to this role, she held the positions of SVP and General Manager for the Cardiovascular and Adult/Adolescent Vaccine franchises and VP & GM for the HPV and New Products franchises. Before joining Merck, Bev worked as a healthcare consultant in New York; as a Special Assistant to the Executive Director of US Department of Health and Human Services; and as a Nurse Manager at the Thomas Jefferson University Hospital critical care unit in Philadelphia, PA. Bev holds a BS in Nursing from Trenton State College and earned her MBA from the Wharton School, University of Pennsylvania. 

Research Interest

 pharmaceutics